NeoImmuneTech, Inc. (KOSDAQ:950220)
South Korea · Delayed Price · Currency is KRW 1,767.00
-738.00 (-29.46%)
Jun 10, 2026, 3:30 PM KST
NeoImmuneTech Revenue
NeoImmuneTech had revenue of 526.98M KRW in the quarter ending March 31, 2026, with 3,881.69% growth. This brings the company's revenue in the last twelve months to 608.57M, up 231.43% year-over-year. In the year 2025, NeoImmuneTech had annual revenue of 94.82M, down -44.35%.
Revenue (ttm)
608.57M
Revenue Growth
+231.43%
P/S Ratio
287.07
Revenue / Employee
11.70M
Employees
52
Market Cap
174.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 94.82M | -75.56M | -44.35% |
| Dec 31, 2024 | 170.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EASY BIO,Inc. | 490.70B |
| Bioneer | 338.01B |
| Macrogen | 199.60B |
| BINEX | 164.00B |
| GC Cell | 163.35B |
| JETEMA, | 77.07B |
| HLB Therapeutics | 67.56B |
| Anterogen.Co.,Ltd. | 8.06B |